MedPath

Cologne Placenta Cohort (CPC)

Conditions
Obesity, Maternal
Gestational Diabetes Mellitus in Pregnancy
Interventions
Other: no intervention
Registration Number
NCT05424965
Lead Sponsor
Sarah Appel
Brief Summary

Aim of the study was to determine if signaling pathways in placentas of mothers affected by overweight/obesity or by gestational diabetes are altered compared to placentas of a control group (normal weight, no gestational diabetes). Moreover, maternal blood and umbilical cord blood were analysed.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
247
Inclusion Criteria
  • singleton pregnancy
  • BMI before pregnancy >= 18
  • with & without gestational diabetes
  • c-section at gestational week 35+0 until 41+6
Exclusion Criteria
  • multiple pregnancy
  • maternal serious internal disease
  • infections before pregnancy (e.g. HIV, hepatitis B)
  • pregnancy-associates diseases (e.g. gestoses, androgen insensitivity syndrome)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
obese without gestational diabetesno interventionBMI \>= 30; normal glucose tolerance
normal weight with gestational diabetesno interventionBMI \< 25; impaired oral glucose tolerance
overweight with gestational diabetesno interventionBMI 25 - 29.9; impaired glucose tolerance
overweight without gestational diabetesno interventionBMI 25 - 29.9; normal glucose tolerance
obese with gestational diabetesno interventionBMI \>= 30; impaired glucose tolerance
normal weight without gestational diabetesno interventionBMI \< 25; normal glucose tolerance
Primary Outcome Measures
NameTimeMethod
Activity of Wnt signaling pathway in placental tissuethrough study completion, about 4 years in total

Analysis of components of the Wnt signaling pathway; like LRP6 receptor, beta-Catenin, GSK3beta, Wnt ligands (=proteins of interest) and an appropriate protein for normalization.

Total protein lysates of placental tissue will be used. Analysis will be performed by western blotting and subsequent densitometric analysis. Outcome measure will be \[relative protein level of protein or interest/relative protein level of normalization protein\].

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University Hospital of Cologne

🇩🇪

Cologne, NRW, Germany

© Copyright 2025. All Rights Reserved by MedPath